In-Vivo Ovine Study Demonstrates Sustained Performance Of Company’s Continuous Blood Glucose Monitoring (CBGM) Technology Over 240 Days, Reinforces Path to Key IDE SubmissionRUTHERFORD, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the publication of a peer reviewed scientific article in The Journal ...